Compare ACET & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | BDSX |
|---|---|---|
| Founded | 1947 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | ACET | BDSX |
|---|---|---|
| Price | $0.54 | $7.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 1.9M | 62.9K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | N/A | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.45 | $3.44 |
| 52 Week High | $1.12 | $32.20 |
| Indicator | ACET | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 33.71 | 51.69 |
| Support Level | $0.53 | $7.68 |
| Resistance Level | $0.57 | $8.17 |
| Average True Range (ATR) | 0.05 | 0.66 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 5.35 | 55.68 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.